National Partnership to Improve Dementia Care in Nursing Homes: Antipsychotic Medication Use Data Report (October 2019)
The National Partnership to Improve Dementia Care in Nursing Homes is committed to improving the quality of care for individuals with dementia living in nursing homes. The National Partnership has a mission to deliver health care that is person-centered, comprehensive and interdisciplinary with a specific focus on protecting residents from being prescribed antipsychotic medications unless there is a valid, clinical indication and a systematic process to evaluate each individual’s need. The Centers for Medicare & Medicaid Services (CMS) promotes a multidimensional approach that includes; research, partnerships and state -based coalitions, revised surveyor guidance, training for providers and surveyors and public reporting.
CMS is tracking the progress of the National Partnership by reviewing publicly reported measures. The official measure of the Partnership is the percentage of long-stay nursing home residents who are receiving an antipsychotic medication, excluding those residents diagnosed with schizophrenia, Huntington's Disease or Tourette’s Syndrome. In 2011Q4, 23.9 percent of long-stay nursing home residents were receiving an antipsychotic medication; since then there has been a decrease of 40.1 percent to a national prevalence of 14.3 percent in 2019Q2. Success has varied by state and CMS region, with some states and regions having seen a reduction of greater than 45 percent. CMS acknowledges that circumstances exist where clinical indications for the use of antipsychotic medications are present and does not expect that the national prevalence of antipsychotic medication use will decrease to zero.
National Partnership to Improve Dementia Care in Nursing Homes: Late Adopter Data Report (October 2019)
CMS announced that the National Partnership met its goal of reducing the national prevalence of antipsychotic medication use in long-stay nursing home residents by 30 percent by the end of 2016. It also announced a new goal of a 15 percent reduction in those homes with currently limited reduction rates. Nursing homes with low rates of antipsychotic medication use are encouraged to continue their efforts and maintain their success, while those with high rates of use are to work to decrease antipsychotic medication use by 15 percent for long-stay residents by the end of 2019, using the prior baseline rate (2011Q4). These homes have been identified as late adopters.
Nursing homes were identified as late adopters, based upon 2017Q1 data. These nursing homes continued to have a high rate of antipsychotic medication use, their percentage of change from 2011Q4 to 2017Q1 increased or decreased very little, and they remained above the national average in 2017Q1. This quarterly data report is specific to the progress of the late adopters. In 2011Q4, 21.4 percent of long-stay nursing home residents, living in a nursing home identified as a late adopter, were receiving an antipsychotic medication; since then there has been a decrease of 13.7 percent to a national prevalence, among late adopters, of 18.5 percent in 2019Q2. For more information on the National Partnership, please send correspondence to firstname.lastname@example.org.